ReviewMolecular pharmacology2026
Oligomerization of transmembrane adenylyl cyclase isoforms.
Review in Molecular pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Membrane-bound adenylyl cyclases (ACs) function as vital enzymes that convert external signals into intracellular responses through the second messenger cAMP. Traditionally viewed as monomers, ACs are now recognized to form oligomers, introducing new regulatory mechanisms. This minireview synthesizes emerging structural and biochemical evidence for AC oligomerization and explores its functional significance. Oligomerization plays a critical role in the localization of ACs by regulating retention in the endoplasmic reticulum, membrane targeting, and distribution within signaling microdomains. Functional data suggest that dimer/oligomer interfaces act as regulatory nodes, although isoform-specific differences in oligomer architecture and functional consequences remain poorly understood. Defining the mechanisms underlying these differences is a critical area for future investigation. Importantly, the structural variability of oligomer interfaces, relative to conserved catalytic domains, offers new therapeutic potential that may enable isoform-selective modulation of AC activity. By integrating past and current research, this review frames oligomerization as a fundamental, yet underexplored, determinant of cAMP signaling. Advancing our understanding of the assembly, regulation, and dynamics of AC oligomers may open new avenues for precise control of cAMP signaling in both physiological and pathological contexts. SIGNIFICANCE STATEMENT: Oligomerization of membrane adenylyl cyclases adds regulatory complexity to cAMP signaling by modulating catalytic activity, localization, and compartmentalization. Distinct homo- and hetero-oligomers may underlie isoform-specific functions and offer new therapeutic opportunities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.